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Abstract
Bacterial translocation from the gut and subsequent immune activation are hallmarks of HIV infection and are thought to
determine disease progression. Intestinal barrier integrity is impaired early in acute retroviral infection, but levels of plasma
lipopolysaccharide (LPS), a marker of bacterial translocation, increase only later. We examined humanized mice infected with HIV
to determine if disruption of the intestinal barrier alone is responsible for elevated levels of LPS and if bacterial translocation
increases immune activation. Treating uninfectedmice with dextran sodium sulfate (DSS) induced bacterial translocation, but did
not result in elevated plasma LPS levels. DSS-induced translocation provoked LPS elevation only when phagocytic cells were
depleted with clodronate liposomes (clodrolip). Macrophages of DSS-treated, HIV-negative mice phagocytosed more LPS ex vivo
than those of control mice. In HIV-infected mice, however, LPS phagocytosis was insufficient to clear the translocated LPS. These
conditions allowed higher levels of plasma LPS and CD8+ cell activation, which were associated with lower CD4+/CD8+ cell ratios
and higher viral loads. LPS levels reflect both intestinal barrier and LPS clearance. Macrophages are essential in controlling
systemic bacterial translocation, and this function might be hindered in chronic HIV infection.
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Introduction
The clinical course of HIV infection varies considerably among
patients, and the variability is even greater in simian models. Asian
monkeys infected with simian immunodeficiency virus (SIV) rapidly
progress to AIDS, but Africanmonkeys do not get sick [1]. In general,
a pathogenic course of retroviral infection is characterized by high
levels of immune activation [2], and bacterial translocation from the
intestinal tract has been implicated as an underlying activating
mechanism [3–8]. The integrity of the intestinal barrier is impaired
early in acute retroviral infections [9], and a substantial fraction of the
intestinal CD4+ T cells are lost within days after infection [10,11].
However, bacterial translocation manifests itself only later. Low
T-cell numbers in the gut are an important characteristic of HIV
or SIV pathogenesis [12,13], but intestinal CD4+ T-cell depletion
does not predict the outcome of SIV infection in monkeys [14]. In
SIV-infected African monkeys, for example, bacterial transloca-
tion is prevented despite low numbers of intestinal CD4+ T cells
[15]. Thus, intestinal CD4+ T-cell depletion alone cannot explain
bacterial translocation and the subsequent rise in plasma
lipopolysaccharide (LPS) levels in chronic HIV infection [8].
Preferential depletion of Th17 cells is associated with disruption of
the intestinal barrier in pathogenic retroviral infections [16,17],
but overall, the mechanism linking bacterial translocation and
HIV pathogenesis is not fully understood.
Seeking evidence for this mechanism, we examined relationships
among intestinal barrier integrity, microbial translocation, immune
activation, and HIV replication in a mouse-model of HIV infection.
In this model, RAG22/2gammac
2/2 mice are transplanted with
human cord-blood hematopoietic stem cells. A human lymphoid
system develops [18], and the ‘‘humanized’’ mice can be infected
withHIV [19–21]. The humanized mice combine the advantages of
studying HIV in human cells and in a small-animal model that
facilitates experimental manipulations. Furthermore, these mice
have low intestinal lymphocyte numbers [22]. In HIV infection, low
numbers result mostly from virus-mediated depletion. In the
humanized mice, however, they result from a low local level of
engraftment by human cells. Thus, in the humanized mice, low
numbers of intestinal T cells are uncoupled from the effects of viral
replication. Moreover, the intestinal barrier can be disrupted by
adding dextran sodium sulfate (DSS) to the drinking water of mice
[23]. DSS treatment leads to apoptosis [24] and reduced
proliferation of intestinal epithelial cells [25], mimicking the
enterocyte apoptosis seen in SIV infection [26].
In the current study, we dissected the effects of bacterial
translocation alone or in the context of HIV infection by
combining DSS and HIV in humanized mice. We defined the
consequences of HIV infection and bacterial translocation on
plasma LPS levels, LPS clearance by macrophages, immune
activation, and T-cell loss.
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Results
DSS treatment or HIV infection induce a similar amount
of bacterial translocation
In a DSS dose-response experiment, we established a treatment
protocol that increases bacterial translocation without inducing
colitis (Fig. S1). Briefly, we quantified bacterial translocation in
groups of HIV-uninfected and -infected mice with mock or DSS
treatment (i.e., HIV2/DSS2, HIV2/DSS+, HIV+/DSS2, or
HIV+/DSS+ mice). We infected humanized mice with the CCR5-
tropic HIV strain YU-2 and verified the infection by RT-PCR of
plasma HIV RNA 4–6 weeks after inoculation. Thereafter, infected
and uninfected control mice were treated with 0 or 0.75%DSS for 2
weeks. We cultured organ suspensions of mesenteric lymph nodes
(MLN) and spleens, quantified bacterial colonies (Fig. 1A), and
calculated a translocation index, based on quantity, diversity, and
location of recovered bacteria (Fig. 1B). HIV2/DSS2 control mice
showed some baseline translocation with roughly a third of the
animals containing bacteria in the MLN suspensions. Only few
animals showed systemic dissemination to the spleen. DSS
treatment increased bacterial translocation; in HIV2/DSS+ mice
percentages of cultures containing bacteria doubled, and particu-
larly in the spleen bacterial loads were higher. Organ cultures
yielded mainly Lactobacilli, Staphylococcus xylosus, a typical mouse
commensal, and Enterococci, whereas stool cultures yielded a
multitude of aerobic and anaerobic bacteria. Only some bacterial
species translocated to the organs in sufficient numbers to be
cultured. HIV+ mice had similar microbiology results to HIV2/
DSS+ mice. Overall, the range and amount of translocation were
comparable between HIV2/DSS+, HIV+/DSS2, and HIV+/
DSS+ mice. HIV infection alone seemed to facilitate bacterial
invasion from the gut, and DSS treatment did not further increase
the bacterial translocation in HIV+ humanized mice.
Bacterial translocation does not always induce LPS
elevation
In humans bacterial translocation is quantified by measuring
surrogate markers, such as plasma LPS, soluble CD14 (sCD14), or
LPS binding protein (LBP). We compared these markers to the
direct measurement of intestinal barrier function in humanized
mice.
Plasma LPS measurements showed a contrasting picture to
microbiology results. Only HIV+ mice exhibited elevated levels of
LPS in the systemic circulation. HIV2/DSS+ mice, which had
increased intestinal permeability according to the organ culture
results, controlled plasma LPS levels (Fig. 1C). In accordance
with the elevated LPS levels, HIV+ mice also exhibited higher
plasma sCD14 and LBP levels (Fig. 1D and E). We did not
measure endotoxin core antibodies (EndoCAb) since humanized
RAG22/2gammac
2/2 mice in general have very poor antibody
responses, serum immunoglobulin concentrations are several log
lower than in humans [18], and mostly IgM is produced with IgG
appearing only several months after humanization [20].
The HIV+ mice might have had a greater influx of smaller
bacterial products and as a consequence higher plasma LPS levels.
To eliminate this possibility, we measured the integrity of the
intestinal barrier by gavaging mice with fluorescein isothiocyanate
(FITC)-dextran with a molecular weight similar to that of LPS
(Fig. S2B). Furthermore, we included wild-type and non-humanized
mice to determine the consequences of irradiation and transplan-
tation. After 4 hours, FITC-dextran was detected at similar
concentrations in the plasma of HIV2/DSS2 control mice, wild-
type BALB/c, and non-humanized RAG22/2gammac
2/2 mice.
Thus, independent of humanization, RAG22/2gammac
2/2 and
wild-type mice had equal intestinal permeabilities, and the absence
of intestinal lymphocytes had little effect on permeability in this
model. In DSS-treated or HIV-infected mice there was a trend
towards higher FITC-dextran values. In histological sections of the
intestines, we found no evidence for exacerbated damage in HIV+
mice, and DSS-treated mice showed moderate changes (Fig. S2A).
Defects in intestinal barrier integrity influenced translocation,
but alone they were not sufficient to induce LPS elevation. In
HIV-infected mice, some additional factors contributed to higher
plasma LPS levels.
Bacterial translocation can be compensated for by
increased macrophage phagocytosis
We hypothesized that plasma LPS levels are a marker for
bacterial translocation and for the clearance of bacterial products
from the systemic circulation. One of the main LPS clearance
mechanisms is phagocytosis by liver macrophages [27,28]. We
tested the influence of LPS clearance on plasma LPS levels by
depleting macrophages in the humanized mice. Clodronate
liposomes induce apoptosis of phagocytic cells, thus humanized
mice injected with clodronate liposomes exhibited a strong
reduction of macrophage numbers (Fig. 2A). When we simulta-
neously treated the mice with 0.75% DSS for 1 week, plasma LPS
levels increased (Fig. 2B). Disturbing the intestinal barrier or
reducing the number of macrophages alone caused no change in
plasma LPS.
To assess macrophage function during HIV infection, we isolated
liver macrophages from all four groups of mice (i.e., HIV2/DSS2,
HIV2/DSS+, HIV+/DSS2, and HIV+/DSS+ mice) and incu-
bated the cells ex vivo with FITC-LPS (Fig. 2C). All macrophages
took up some LPS, but cells isolated from HIV2/DSS+ mice up-
regulated their phagocytic capacity significantly compared to cells
from control animals. Cells from HIV+ mice showed a slight,
statistically insignificant increase of LPS phagocytosis (Fig. 2D).
Further evidence of altered macrophage function in HIV+mice was
an increase of pro-inflammatory cytokines, such as IL-12 and TNF-
alpha in the plasma (Fig. S3). Macrophage numbers in liver and
intestines were similar in all groups (data not shown). The results
imply that bacterial translocation and LPS influx can be
Author Summary
HIV infection leads to continuous destruction of the body’s
immune defenses. Furthermore, disease progression is
linked to heightened levels of immune activation. Howev-
er, the underlying activating factors and their relationships
to HIV pathogenesis are controversial. In patients with
chronic HIV infection, bacteria and their products, such as
lipopolysaccharide (LPS), translocate from the intestinal
lumen into the systemic circulation. In the current study,
we investigated the pathogenic potential of bacterial
translocation in HIV-infected humanized mice. By modu-
lating the amount of bacterial translocation in the mice,
we determined that LPS elevation depends on intestinal
barrier dysfunction and defective LPS clearance by
macrophages. HIV-infected mice showed inadequate LPS
clearance, leading to a cascade of uncontrolled bacterial
translocation, T-cell activation, HIV replication, and T-cell
loss. Our study highlights how important the interplay
between different immune cells is for maintaining a
healthy balance between immune activation with the goal
to defend the body against microbes and detrimental
activation that fuels HIV replication.
LPS Clearance Affects HIV Pathogenesis
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Figure 1. Gastrointestinal barrier dysfunction did not completely explain HIV-associated plasma LPS elevation in humanized mice.
4 to 6 weeks after HIV or mock infection, humanized mice received DSS 0.75% or normal drinking water for 2 weeks. (A) In cultures of organ
suspensions, bacterial colony forming units from MLN (white bar) and spleens (black bar, mean, SD) were quantified; percentages of positive organs
in the different groups are indicated at the bottom of the respective bars (n = 50, pooled data from two independent experiments). (B) The mice
showed a trend towards higher levels of bacterial translocation (assessed by an index that includes number, species, and location of bacteria
detected, P = 0.1, 0.08 and 0.13, respectively) after HIV infection or DSS treatment. (C) DSS+/HIV2mice (black square) had plasma LPS levels similar to
those of control mice (black circle). Only HIV+ mice without (white circle, *, P = 0.015) or with DSS treatment (white square, **, P = 0.005) showed
LPS Clearance Affects HIV Pathogenesis
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compensated for by increased LPS phagocytosis and that this
function was disturbed in HIV-infected mice.
Bacterial translocation activates T cells
Since bacterial translocation has been implicated in immune
activation during chronic HIV infection, we examined the effects
of bacterial translocation alone or in the context of HIV infection
on the expression of cell-surface markers of T-cell activation. We
determined T-cell activation levels in the spleens of humanized
mice by measuring percentages of CD38 HLA-DR double positive
cells in human CD4+ or CD8+ cells (Fig. 3A). CD4+ cells from
HIV2/DSS+ animals showed a slight increase of activation, but
activation of CD8+ cells was more apparent (Fig. 3B). Both groups
of HIV-infected mice had even higher CD8+ cell activation levels,
with no difference between DSS2 and DSS+ groups. There was a
trend towards slightly higher CD4+ cell activation in HIV+ mice.
Thus, bacterial translocation, even if no detectable plasma LPS
elevation occurred, activated CD4+ and CD8+ cells in HIV- mice.
In HIV+ mice, where levels of plasma LPS were increased, CD8+
cell activation was even stronger.
T-cell activation promotes viral replication and CD4+
T-cell loss
In HIV- mice, levels of CD4+ and CD8+ cell activation were
tightly correlated (Fig. 4A). If that relationship of CD4+ and CD8+
cell activation was the same in HIV+ mice, then CD4+ cell
activation levels should have been even higher in HIV+ mice than
in HIV2/DSS+ mice. The correlation between activation levels
of CD4+ and CD8+ cells in HIV+ mice, however, was partially
lost (Fig. 4B), and the HIV+ mice had a relative deficit of activated
CD4+ cells.
In humanized mice, absolute CD4+ T-cell numbers differ,
because the efficiency of human engraftment is variable. However,
CD4+/CD8+ cell ratios are independent of engraftment and are,
thus, reasonably reliable estimates of CD4+ cell depletion. The
ratios were similar for all four groups (Fig. S4A). Individual
variations of CD4+/CD8+ cell ratios between mice were probably
too large to detect small changes between groups in the relatively
short time of the experiment. Furthermore, no difference in HIV
replication was observed between HIV+/DSS2 and HIV+/DSS+
mice (Fig. S4B). Nevertheless, in HIV+ mice, percentages of
activated CD8+ cells correlated with lower CD4+/CD8+ cell
ratios (Fig. 4C). Hence, HIV+ mice with high levels of CD8+ cell
activation lost more CD4+ cells. No correlation between CD4+/
CD8+ cell ratios and CD8+ cell activation was seen in HIV2 mice
(data not shown, P= 0.423, r = 0.190). In the absence of HIV
infection, no loss of CD4+ cells occurred, indicating that HIV
causes the preferential loss of activated CD4+ cells. Indeed, higher
CD8+ cell activation levels—this time calculated in relation to
total splenocytes to take engraftment level also into account—
correlated with higher viral loads (Fig. 4D). In the HIV+
humanized mice, activation of CD4+ cells seemed to be masked
by HIV infection and rapid loss of these cells, maybe even before
full expression of activation markers.
Discussion
Dysfunction of the intestinal barrier has severe consequences for
the whole organism. It leads to translocation of bacteria from the gut
and mediates inflammation. In chronic HIV infection, for instance,
elevated levels of circulating bacterial products are associated with
T-cell activation and disease progression [8]. We established a
humanized mouse model of intestinal barrier dysfunction to
determine the systemic effects of bacterial translocation. In our
model, permeability corresponded well with translocation. But
plasma LPS levels, the classical marker of bacterial translocation,
depended only partially on barrier dysfunction. Macrophages
compensated for the increased bacterial translocation by up-
regulating their phagocytic capacity and thereby kept plasma LPS
levels in a normal range. In HIV-infected mice, however, LPS
clearance was inadequate leading to increased plasma LPS levels,
high T-cell activation, and vigorous HIV replication.
A multilayered barrier protects the body from invading
intestinal bacteria. The first line of defense is a tight, mucus-
coated sheath of intestinal epithelial cells. Moreover, leukocytes in
the underlying lamina propria contribute to the protection against
bacteria. The humanized mice we used have low intestinal
lymphocytes numbers [22]. Therefore, changes of the epithelial
integrity probably have a relatively big impact on translocation in
humanized mice, even without obvious histopathological changes.
While there was no obvious difference in FITC-dextran
translocation between humanized and wild-type mice, intestinal
permeability tended to increase after HIV infection or low dose
DSS treatment (Fig. S2B). Notably, HIV+ mice had high plasma
TNF-alpha levels (Fig. S3). TNF-alpha disrupts tight junctions and
induces apoptosis of intestinal epithelial cells [29], thereby
mediating barrier dysfunction. Baseline translocation in HIV2/
DSS2 mice was quite high with one third of the MLN cultures
containing bacteria (Fig. 1A and B). HIV+ or DSS+ mice more
frequently had bacteria translocating to MLN and spleen—in
accordance with the increased FITC-dextran permeability. From
our data, it is not possible to infer the exact role disturbance of
epithelial permeability and intestinal lymphocyte depletion plays
in human HIV infection. But in general, the amount of bacterial
translocation depends on barrier integrity.
Surprisingly, plasma LPS levels showed a different pattern
(Fig. 1C). They did not depend strictly on permeability and
translocation. In our experiments, HIV+ mice had elevated
plasma LPS levels. HIV2/DSS+ mice controlled the increased
influx of bacteria from the gut by raising their ability to clear LPS.
LPS elevation only occurred in animals that had disturbance of the
intestinal barrier and at the same time LPS clearance defects,
either because of macrophage depletion or HIV infection (Fig. 2).
Thus, macrophage phagocytosis seems to be critical in protecting
against systemic translocation and failed clearance leads to
systemic elevation of bacterial products. This hypothesis is
supported by studies of inflammatory bowel disease. Plasma LPS
levels are elevated in active inflammatory bowel disease, when the
intestinal barrier is disrupted [4]. Furthermore, patients with
Crohn’s disease clear subcutaneously injected bacteria very slowly,
their macrophages secrete few pro-inflammatory cytokines in
response to bacteria or TLR ligands, and the transcription profiles
of these macrophages show defects in vesicle trafficking and
cytoskeletal organization [30]. This indicates that defects similar to
the dysfunctional phagocytosis seen in our model might be
important in inflammatory bowel diseases.
The mechanism leading to macrophage dysfunction in HIV+
mice is not clear. It is tempting to postulate induction of an
significant increases of plasma LPS (n = 59, pooled data from two independent experiments). (D and E) Both groups of HIV+ mice showed a trend
towards higher plasma sC14 (P = 0.06 for HIV+/DSS2 and P=0.1 for HIV+/DSS+mice) and had significantly higher LBP values (***, P = 0.0006 for HIV+/
DSS2 and **, P = 0.008 for HIV+/DSS+ mice).
doi:10.1371/journal.ppat.1000867.g001
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Figure 2. The combination of bacterial translocation and disturbed LPS clearance induced plasma LPS elevation. (A) Humanized mice
were injected intraperitoneally with clodrolip (1 mg/20 g body weight) to deplete phagocytic CD11b intermediate cells (spleens of representative
mock PBS or clodrolip treated mice 48 h after injection). (B) After 1 week of DSS 0.75% (square, block arrow down) treatment and a second injection
of clodrolip (0.5 mg/20 g body weight) (block arrow up, block arrow down), plasma LPS was only increased in mice that received both treatments (*,
P = 0.006, n = 37, pooled data from two independent experiments). (C) Liver macrophages, isolated from HIV2 or HIV+ mice that received either
normal drinking water or 0.75% DSS for 2 weeks, were incubated ex vivo with FITC-LPS at 37uC or 4uC (shaded or open histogram), and mean
fluorescence intensity of phagocytic cells (values upper right corner) was measured. (D) Values were normalized to the mean FITC-LPS signal of cells
from HIV2/DSS2 mice (black circle). DSS-induced bacterial translocation increased FITC-LPS phagocytosis (black square, ***, P,0.0001), but HIV
infection abrogated this effect (white circle, P = 0.2), independent of DSS treatment (white square, P = 0.19) (n = 59, pooled data from two
independent experiments).
doi:10.1371/journal.ppat.1000867.g002
LPS Clearance Affects HIV Pathogenesis
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‘‘endotoxin-tolerant’’ macrophage phenotype in HIV2/DSS+
mice, and loss of tolerance induction in HIV+ mice. Endotoxin
tolerance is characterized by programming of macrophages
towards phagocytosis instead of production of pro-inflammatory
cytokines upon LPS re-exposure [31]. Indeed, plasma IL-12 and
TNF-alpha levels were normal in HIV2/DSS+ mice despite
increased bacterial translocation. In contrast, HIV+ mice had high
levels of pro-inflammatory cytokines (Fig. S3). At the moment, the
factors inhibiting tolerance induction are unknown. Duration of
translocation might play a role: HIV2/DSS+ mice had barrier
dysfunction for the relatively short period of two weeks. Control of
longer lasting translocation might not be as easy. Otherwise, the
pro-inflammatory state generated by HIV infection might
influence macrophage function. Macrophages integrate a broad
range of environmental information. Some cytokines [32] and
bacterial products [33,34] sensitize cells to LPS stimulation.
Furthermore, viral products and/or cytokines produced due to
virus infection interfere with endotoxin tolerance induction in
chronically HCV- [35] or HIV- [36] infected patients. Instead
monocytes from these patients produce more TNF-alpha upon
LPS re-stimulation.
So far, it is unknown if LPS clearance dysfunction also exists in
HIV-positive humans, although some evidence supports the
existence of macrophage defects in chronic HIV infection. Plasma
LPS levels in acutely HIV-infected patients are not elevated [8],
despite early depletion of gut lymphocytes. During treatment
interruption, LPS levels rise only after a few weeks of viral
replication [7]. Early after antiretroviral therapy is stopped, falling
EndoCAb levels indicate functional LPS clearance. Thereafter,
elevation of LPS levels suggests the onset of clearance defects. In
fact, HIV inhibits macrophage maturation [37] and phagocytosis
[38,39]. Monocytes from HIV-infected individuals show impaired
Mycobacterium phagocytosis [40]; Saccharomyces up-take is also
decreased, and LPS-mediated enhancement of phagocytosis is less
than the enhancement in monocytes from healthy donors [41].
Moreover, monocytes from HIV-infected patients show an
attenuated pro-inflammatory cytokine response to LPS stimulation
ex vivo [8,42], maybe due to in vivo pre-stimulation. Serum IL-12
and TNF-alpha levels, which reflect in vivo cytokine production,
are higher [43–46]- similar to the increased cytokine levels we
observed in HIV+ mice. Overall, our findings in HIV-infected
humanized mice resemble the results from HIV-infected humans.
Figure 3. HIV-infected humanized mice had high levels of CD8+ T-cell activation. Control (black symbols) or HIV-infected mice (white
symbols) received normal drinking water (circles) or 0.75% DSS (squares) for 2 weeks. (A) Activation levels in the spleen were determined by flow
cytometry of human HLA-DR and CD38 staining of CD45+CD8+ (one representative animal per group) and CD45+CD4+ splenocytes. (B) DSS
treatment alone slightly increased activation levels of CD4+ (*, P = 0.004) and CD8+ cells (*, P = 0.007), over those in uninfected, untreated control
mice. HIV infection drastically increased CD8+ cell activation in animals that received normal (***, P,0.0001) or DSS (***, P,0.0001) water (n = 50,
pooled data from two independent experiments).
doi:10.1371/journal.ppat.1000867.g003
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Certainly, not all aspects of human HIV infection can be
modeled accurately in humanized mice. For example, direct HIV
infection of macrophages is rare in the mice. Engraftment of
human monocytes was low; less than 2% of all monocytes were of
human origin (data not shown). Most macrophages are of murine
origin and therefore resistant to HIV infection. In humans,
macrophage permissiveness to HIV infection varies from tissue to
tissue. For example, intestinal macrophages are quite resistant to
infection, but vaginal macrophages are readily infected [47].
However, productive infection of macrophages is, in general,
infrequent in vivo [48], except for late stages of disease when
opportunistic infections occur [49]. To definitely determine the
importance of direct viral infection of macrophages, other models
with bigger populations of human myeloid cells would be useful.
Lymphoid engraftment, however, is quite good in humanized
mice. This allowed the investigation of T-cell activation in DSS-
treated or HIV-infected mice. Bacterial translocation induced
CD4+ and CD8+ cell activation (Fig. 4). Other activating factors
(i.e., stimulation of TLR7/8 by HIV RNA [50–52]) might also
have played a role. However, in HIV2/DSS+ mice, such other
activating factors were not present, and bacterial translocation
alone activated T cells. Since plasma LPS levels were not elevated
in these mice, immune activation might have been mediated by
other bacterial components, such as peptioglycan, flagellin, or
bacterial DNA. Moreover, LPS flux—input from the gut and
subsequent clearance—was greater in these mice. A greater LPS
flux might activate the immune system. At least, it induced and
sustained stimulation of macrophage phagocytosis. Uncontrolled
bacterial translocation, as seen in HIV+ mice, might reasonably
caused higher levels of lymphocyte activation. Not surprisingly,
DSS treatment had no effect on T-cell activation in HIV+ mice.
The bacterial translocation indices and LPS phagocytosis
Figure 4. Activation of CD8+ cells was associated with lower CD4+/CD8+ cell ratios and higher viral loads. Human CD8+ splenocyte
activation levels defined by HLA2DR+ and CD38+ co-staining from HIV2/DSS2 (black circle), HIV2/DSS+ (black square), HIV+/DSS2 (white circle),
and HIV+/DSS+ animals (white square) were correlated with CD4+ cell-activation levels, CD4+/CD8+ cell ratio, and viral load. (A) In uninfected mice,
activation levels of CD8+ and CD4+ cells were tightly correlated (n = 23, pooled data from two independent experiments). (B) But in HIV+ mice, this
relationship was not as clear (n = 27, pooled data from two independent experiments). (C) In HIV+ mice, higher percentages of activated CD8+ cells
correlated with lower CD4+/CD8+ cell ratios. (D) When activation levels were adjusted for overall engraftment by calculating percentages of HLA-
DR+CD38+CD8+ cells of total cells, including murine cells, CD8+ cell activation correlated also with higher viral loads.
doi:10.1371/journal.ppat.1000867.g004
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capacities were almost identical in HIV+/DSS2 and HIV+/
DSS+ groups, leading to similar LPS, LBP and sC14 levels and,
therefore, to similar activation levels.
Our results might explain why levels of CD8+ T-cell activation
are especially good markers of disease outcome [53], even though
CD8+ T cells are not direct viral targets. In HIV-uninfected mice
CD8+ and CD4+ cell activation levels were tightly correlated.
Thus, CD8+ T-cell activation levels seem to predict the amount of
activated and HIV-permissive CD4+ T cells. These cells have a
very short lifespan; the half-life of an infected CD4+ T cell is
estimated at 1.6 days [54]. Additionally, measurements of
lymphocyte telomere lengths indicate that, in HIV-infected
individuals, only CD8+ T-cell turnover is increased, while
telomeres in CD4+ T cells show no excessive turnover [55].
CD4+ T cells might be lost due to HIV infection before cell
division is accomplished. This could also explain the relative deficit
of activated CD4+ cells we observed in HIV+ animals. HIV
preferably infects activated CD4+ cells [56]. Indeed, those mice
with the highest percentages of activated CD8+ cells had the
lowest CD4+/CD8+ cell ratios and the highest HIV plasma loads.
In conclusion, we identified a critical role of macrophages in
protection from systemic bacterial translocation. In humanized
mice, failure of LPS clearance was associated with high levels of T-
cell activation and HIV replication. Macrophage dysfunction
might be an underestimated mechanism in HIV-induced immu-
nodeficiency and certainly warrants further investigation.
Materials and Methods
Ethics statement
All experiments were approved by ethical committees of the
University Zurich and the Federal Veterinary Department and
were conducted according to local guidelines (TschV, Zurich) and
the Swiss animal protection law (TschG). Cord blood was collected
with written consent of the parents.
Generation and HIV infection of humanized mice
Mice were reconstituted and infected as described [19]. Briefly,
newborn RAG22/2gammac
2/2 mice were irradiated with
262 Gy. CD34+ cells were isolated from human cord blood with
immunomagnetic beads (Miltenyi Biotec), and 2.7560.56105 cells
were transplanted into each mouse. After 10 to 16 weeks, the
degree of blood engraftment was determined by flow cytometry of
peripheral blood mononuclear cells stained for the panhuman
marker CD45 in all mice (mean human cells/live cells 5.665.4%
SD). Mice were infected intraperitoneally with HIV YU-2, 26105
of the tissue-culture infectious dose50 per mouse. Plasma viral loads
were measured by RT-PCR (Amplicor, Roche) 4–6 weeks after
inoculation and at the end of each experiment. The detection limit
was 1,600 HIV RNA copies/ml. Activation levels of T cells were
measured by flow cytometry of splenocytes stained for human
CD45, CD4, CD8, HLA-DR, CD38, and appropriate isotype
controls (all from BD Biosciences). In all experiments, mouse litters
and cord blood donors were evenly distributed to all experimental
groups.
Induction and measurement of bacterial translocation
Bacterial translocation was induced by adding 0.75% (w/v) DSS
(molecular weight 40,000, MP Biomedicals) to the drinking water
for 2 weeks. Spleen and MLN were removed aseptically, mashed
with a pestle in PBS, and plated on sheep blood and MacConkey
agar plates. Plates were only incubated aerobically, since in a pilot
experiment, no anaerobic bacteria could be detected in organ
cultures. As a control, diluted stool samples were cultured both in
aerobic and anaerobic conditions. A descriptive bacterial translo-
cation index was calculated from organ culture results (no bacterial
growth = 0 points, 10 to 99 cfu/organ = 1 point, 100 to 999 cfu/
organ = 2 points, .1000 cfu/organ = 3 points, for all organs
points were multiplied by the number of bacterial species detected.
For spleen cultures, points were doubled, and finally, all points
from one mouse were added up). LPS was quantified by endpoint
chromogenic limulus amoebocyte lysate assay (Lonza). Plasma
samples were diluted 1:10 with endotoxin free water, incubated at
85uC for 12 min, and assayed according to the manufacturer’s
instructions. Standard endotoxin (Lonza) was diluted to cover
plasma LPS values within a range of 0.5 to 20 EU/ml. Plasma
mouse sCD14 and LBP were measured by ELISA (both from
CellSciences), according to the manufacturer’s instructions. For
sCD14 measurement, samples were diluted 1:150, and for LBP
measurement, 1:800.
Ex vivo LPS phagocytosis
Liver mononuclear cells were isolated by Ficoll-Hypaque
density gradient centrifugation. To further purify macrophages,
cells were incubated for 3 h in RPMI, 10% FCS, penicillin/
streptomycin, and L-glutamine at 37uC, 5% CO2, and then
washed two times with room temperature PBS to remove non-
adherent cells. This procedure yielded over 90% murine CD11b+
cells. Cells were then incubated with 0.1 mg/ml FITC-LPS
(Sigma) in RPMI, 10% FCS, penicillin/streptomycin, and L-
glutamine at 37uC, 5% CO2 for 1 h. As a control, cells were also
incubated with FITC-LPS at 4uC. Cells were then washed two
times with cold PBS, detached with trypsin, washed once again,
and analyzed by flow cytometry. FITC-LPS mean fluorescent
intensity was normalized to the fluorescence of samples from
HIV2/DSS2 mice.
Macrophage depletion
Mice were injected intraperitoneally with clodrolip (1 mg/20 g
body weight) or with PBS [57]. After 48 h, depletion was verified
in four mice by staining of spleen and liver cells for CD11b. To
maintain depletion, mice were treated a second time with clodrolip
0.5 mg/20 g body weight or with PBS intraperitoneally 4 days
after the first injection. Concurrently, half of the mice received
DSS 0.75% (w/v) in their drinking water. After 1 week, the mice
were sacrificed, and their plasma LPS levels were measured.
Statistical analysis
GraphPad Prism 5.02 was used for statistical analysis. Data
were analyzed by parametric one-way analysis of variance,
followed by Bonferroni post-test. All p-values shown are adjusted
for multiple comparisons. In the figures, p-values are presented for
comparisons between treatment groups and controls and are
denoted by asterisks. Values for HIV/DSS experiments for plasma
LPS, viral load, FITC-dextran fluorescence, and percentages of
activated CD8+ cells (of total cells) were log transformed before
analysis to reduce right-skewing of the data. For all correlations,
Pearson’s correlation coefficient was calculated. In all figures,
points represent values of individual mice, and lines depict mean
values.
Supporting Information
Figure S1 DSS induced bacterial translocation in humanized
mice. 16 uninfected mice were treated with different doses of DSS
in the drinking water for 2 weeks. (A) Systemic bacterial load was
assessed by semi-quantitative (+ black bar, ++ white bar, +++)
microbiological culture of organ suspension from mesenteric
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lymph nodes, spleen and liver. (B) Mouse weight as an indicator
for diarrhea and colitis was measured daily (mean). This
experiment was done once.
Found at: doi:10.1371/journal.ppat.1000867.s001 (0.32 MB
TIF)
Figure S2 Histological and functional measurement of the
intestinal integrity. (A) Formalin fixed, haematoxylin and eosin
stained tissue sections of HIV infected and/or DSS treated mice
showed moderate changes of the intestinal mucosa. DSS treatment
induced villus blunting, a modest vessel dilation (*) and discreet
goblet cell hyperplasia (.). (B) Humanized mice (n=32, pooled data
from two independent experiments) were infected with HIV (white
symbols) or mock treated (black symbols) and 4 weeks later received
0 (circles) or 0.75% (squares) w/v DSS. After two weeks, in vivo
permeability was measured by FITC-dextran (molecular weight
10,000, Sigma) translocation. Mice were gavaged with FITC-
dextran 20 mg/20 g body weight in 200 ml PBS and four hours later
FITC fluorescence in the plasma was measured. Wild-type (WT,
block arrow up) and non-humanized RAG22/2gammac
2/2
(RAG2, block arrow down) mice were included as a control.
HIV2/DSS+ mice had higher FITC-dextran plasma values
(*, P=0.012) than WT, non-humanized and HIV2/DSS2 control
mice. Both HIV+ groups showed only a trend towards higher FITC-
dextran translocation.
Found at: doi:10.1371/journal.ppat.1000867.s002 (3.69 MB TIF)
Figure S3 Macrophage derived pro-inflammatory cytokines in
HIV+ mice. We measured plasma cytokine levels by cytometric
bead assay (A.Urwyler, Cytolab) in HIV2/DSS2 (black circle),
HIV2/DSS+ (black square), HIV+/DSS2 (white circle), and
HIV+/DSS+ animals (white square). (A and B) Both human (left)
and murine (right panel) cytokines were assessed. HIV+ mice
showed a trend towards higher human (P= 0.084 and 0.096) and
murine TNF-alpha levels (*, P = 0.045 and P= 0.11 for DSS2 and
DSS+ mice). (C and D) Human IL-12p40 was below detection
limit in many of the animals, while murine IL-12p40 was
significantly elevated in HIV+ mice (***, P= 0.0006, and **,
0.004 for DSS2 and DSS+ mice). IL-1 beta was undetectable in
all mice and IL-6 values showed no significant differences (data not
shown).
Found at: doi:10.1371/journal.ppat.1000867.s003 (0.79 MB TIF)
Figure S4 Diversity of CD4+/CD8+ cell ratios and viral loads in
humanized mice. Humanized mice were infected with HIV (white
symbols) or mock treated (black symbols) and 4 weeks later
received 0 (circles) or 0.75% (squares) w/v DSS. (A) After 2 weeks,
spleens were removed and splenocytes were analyzed for human
CD4+ and CD8+ T-cell ratios by flow cytometry (n = 50, pooled
data from two independent experiments, no significant differenc-
es). (B) Plasma viral load was measured (n= 27, pooled data from
two independent experiments), 48 h before the beginning of DSS
treatment (baseline, no significant difference), and at the end of the
experiment (after DSS, no significant difference).
Found at: doi:10.1371/journal.ppat.1000867.s004 (0.40 MB TIF)
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